You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰宇藥業(300199.SZ):一季度預盈6000萬元–7200萬元 同比扭虧
格隆匯 03-26 20:50

格隆匯3月26日丨翰宇藥業(300199.SZ)公佈2025年第一季度業績預吿,2025年1-3月,公司實現營業收入2.9億元-3.1億元,增長93.00%-106.31%;歸屬於上市公司股東的淨利潤盈利6,000萬元–7,200萬元,上年同期虧損1,410.20萬元;扣除非經常性損益後的淨利潤盈利5,500萬元–6,700萬元。

2024年12月23日,公司向美國食品藥品監督管理局申報的利拉魯肽注射液獲得批准證書,公司此前與海外客户簽署的多肽製劑及原料藥等多個重要訂單陸續完成發貨,並在本期完成相關會計科目的確認,實現公司本期營業收入的增長。

本期公司主要的營業收入來源於海外業務,受益於海外市場需求的持續增長、公司產品的市場競爭力以及嚴格的成本控制等多重因素,海外業務的營業利潤率較高,進一步推動了公司整體盈利水平的提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account